Articles published by Innate Pharma SA
![](https://mms.businesswire.com/media/20230402005026/en/1245155/22/INNATEvertnoirDS.jpg)
Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program
April 03, 2023
From Innate Pharma SA
Via Business Wire
Tickers
IPHA
![](https://mms.businesswire.com/media/20230322005782/en/1245155/22/INNATEvertnoirDS.jpg)
![](https://mms.businesswire.com/media/20230319005001/en/1245155/22/INNATEvertnoirDS.jpg)
![](https://mms.businesswire.com/media/20230315005499/en/1245155/22/INNATEvertnoirDS.jpg)
Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results
March 16, 2023
From Innate Pharma SA
Via Business Wire
Tickers
IPHA
![](https://mms.businesswire.com/media/20230312005034/en/1245155/22/INNATEvertnoirDS.jpg)
![](https://mms.businesswire.com/media/20230220005180/en/1245155/22/INNATEvertnoirDS.jpg)
![](https://mms.businesswire.com/media/20230206005449/en/1245155/22/INNATEvertnoirDS.jpg)
Innate Pharma to Participate in Upcoming Investor Conferences
February 07, 2023
From Innate Pharma SA
Via Business Wire
Tickers
IPHA
![](https://mms.businesswire.com/media/20230124005597/en/1245155/22/INNATEvertnoirDS.jpg)
Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers
January 25, 2023
From Innate Pharma SA
Via Business Wire
Tickers
IPHA
![](https://mms.businesswire.com/media/20230115005037/en/1245155/22/INNATEvertnoirDS.jpg)
![](https://mms.businesswire.com/media/20221218005037/en/1245155/22/INNATEvertnoirDS.jpg)
![](https://mms.businesswire.com/media/20221210005009/en/1245155/22/INNATEvertnoirDS.jpg)
![](https://mms.businesswire.com/media/20221208005422/en/1245155/4/INNATEvertnoirDS.jpg)
![](https://mms.businesswire.com/media/20221130005789/en/1245155/4/INNATEvertnoirDS.jpg)
![](https://mms.businesswire.com/media/20221113005104/en/1245155/4/INNATEvertnoirDS.jpg)
Innate Pharma Reports Third Quarter Financial Results
November 14, 2022
From Innate Pharma SA
Via Business Wire
Tickers
IPHA
![](https://mms.businesswire.com/media/20221106005016/en/1245155/4/INNATEvertnoirDS.jpg)
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update
November 07, 2022
From Innate Pharma SA
Via Business Wire
Tickers
IPHA
![](https://mms.businesswire.com/media/20221103006229/en/1245155/4/INNATEvertnoirDS.jpg)
![](https://mms.businesswire.com/media/20221101005160/en/1245155/4/INNATEvertnoirDS.jpg)
Innate Pharma to Participate in Upcoming Investor Conferences
November 02, 2022
From Innate Pharma SA
Via Business Wire
Tickers
IPHA
![](https://mms.businesswire.com/media/20221019005744/en/1245155/4/INNATEvertnoirDS.jpg)
Innate Pharma 2023 Financial Calendar
October 20, 2022
From Innate Pharma SA
Via Business Wire
Tickers
IPHA
![](https://mms.businesswire.com/media/20220922005753/en/1245155/4/INNATEvertnoirDS.jpg)
![](https://mms.businesswire.com/media/20220914005962/en/1245155/4/INNATEvertnoirDS.jpg)
Innate Pharma Reports First Half 2022 Financial Results and Business Update
September 15, 2022
From Innate Pharma SA
Via Business Wire
Tickers
IPHA
![](https://mms.businesswire.com/media/20220907005694/en/1245155/4/INNATEvertnoirDS.jpg)
Innate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update
September 08, 2022
From Innate Pharma SA
Via Business Wire
Tickers
IPHA
![](https://mms.businesswire.com/media/20220904005030/en/1245155/4/INNATEvertnoirDS.jpg)
Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022
September 05, 2022
From Innate Pharma SA
Via Business Wire
Tickers
IPHA
![](https://mms.businesswire.com/media/20220822005508/en/1245155/4/INNATEvertnoirDS.jpg)
Innate Pharma to Participate in Upcoming Investor Conferences
August 23, 2022
From Innate Pharma SA
Via Business Wire
Tickers
IPHA
![](https://mms.businesswire.com/media/20220807005007/en/1245155/4/INNATEvertnoirDS.jpg)
![](https://mms.businesswire.com/media/20220731005041/en/1245155/4/INNATEvertnoirDS.jpg)
![](https://mms.businesswire.com/media/20220727005690/en/1245155/4/INNATEvertnoirDS.jpg)
![](https://mms.businesswire.com/media/20220706005771/en/1245155/4/INNATEvertnoirDS.jpg)
Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development
July 21, 2022
From Innate Pharma SA
Via Business Wire
Tickers
IPHA
![](https://mms.businesswire.com/media/20220622005572/en/1245155/4/INNATEvertnoirDS.jpg)
![](https://mms.businesswire.com/media/20220510006118/en/1245155/4/INNATEvertnoirDS.jpg)
![](https://mms.businesswire.com/media/20220509005822/en/1245155/4/INNATEvertnoirDS.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.